Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  PROGNOSIS
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Methods of minimal residual disease (MRD) detection in childhood haematological malignancies

100%
Jolkowska J., Derwich K., Dawidowska M.
Journal of Applied Genetics
|
2007
|
vol. 48
|
issue 1
77-83
EN
The appropriate management of haematological disorders must rely on a precise and long-term monitoring of the patient's response to chemotherapy and radiotherapy. Clinical data are not sufficient and that is why in the last decade it became the most important to improve the knowledge of haematological diseases on the basis of molecular techniques and molecular markers. The presence of residual malignant cells among normal cells is termed minimal residual disease (MRD). Nowadays a great progress has been made in the treatment of malignant diseases and in the development of reliable molecular techniques, which are characterised by high sensitivity (10?3? 10?6) and ability to distinguish between normal and malignant cells at diagnosis and during follow-up. Especially, MRD data based on quantitative analysis (RQ-PCR, RT-RQ-PCR) appear to be crucial for appropriate evaluation of treatment response in many haematological malignancies. Implementation of standardized approaches for MRD assessment into routine molecular diagnostics available in all oncohaematological centres should be regarded nowadays a crucial point in further MRD study development.
2

Methods of minimal residual disease (MRD) detection in childhood haematological malignancies

100%
Jolkowska J., Derwich K., Dawidowska M.
Journal of Applied Genetics
|
2007
|
vol. 48
|
issue 3
77-83
EN
The appropriate management of haematological disorders must rely on a precise and long-term monitoring of the patient's response to chemotherapy and radiotherapy. Clinical data are not sufficient and that is why in the last decade it became the most important to improve the knowledge of haematological diseases on the basis of molecular techniques and molecular markers. The presence of residual malignant cells among normal cells is termed minimal residual disease (MRD). Nowadays a great progress has been made in the treatment of malignant diseases and in the development of reliable molecular techniques, which are characterised by high sensitivity (10?3? 10?6) and ability to distinguish between normal and malignant cells at diagnosis and during follow-up. Especially, MRD data based on quantitative analysis (RQ-PCR, RT-RQ-PCR) appear to be crucial for appropriate evaluation of treatment response in many haematological malignancies. Implementation of standardized approaches for MRD assessment into routine molecular diagnostics available in all oncohaematological centres should be regarded nowadays a crucial point in further MRD study development.
3
Content available remote

Plasma homocysteine level and the course of ischemic stroke

100%
Pniewski J., Chodakowska-Zebrowska M., Wozniak R., Stepien K., Stafiej A.
Acta Neurobiologiae Experimentalis
|
2003
|
vol. 63
|
issue 2
127-130
EN
Increased level of homocysteine (Hcy) in blood seems to influence negatively the course of ischemic stroke (IS), the possible mechanism of this action could be acceleration of oxidative stress. The aim of this study is to assess the influence of Hcy level in patients with IS on the prognosis 3 moths after the stroke onset. 75 patients aged 68.27 12.62 years, with the diagnosis of first ever IS were examined. Patients with the symptoms corresponding with TACS at the beginning of stroke and with diminished level of consciousness were not included. The level of Hcy over 15 mol/l was assessed as mild hiperhomocysteinemia (MHcy). 74 (98.7%) patients were assessed 3 months after IS onset in the Rankin scale. Recovery was assessed, according to Rankin Scale: good recovery (GR) 0-2, bad recovery (BR) 3-5 and death. MHcy was seen in 9 (14.5%) with GR and in 8 (66.7%) with BR (P=0,0005). MHcy increases the risk of BR 11.78 times (95%CI 2.93-47.42).
4

Diagnostic value of pancreatic elastase-1 in human acute pancreatitis

100%
Wereszczynska-Siemiatkowska U., Jedynak M., Mroczko B., Siemiatkowski A.
Archivum Immunologiae et Therapiae Experimentalis
|
2003
|
vol. 51
|
issue 3
195-200
EN
The diagnosis of acute pancreatitis is usually confirmed by a significant increase of the serum amylase and/or lipase level. However, serum pancreatic elastase?1 (pEla-1) was found to be a more sensitive diagnostic marker in acute pancreatitis (AP), when assayed by RIA procedure. We analysed the serum concentration of pancreatic elastase-1, measured by ELISA technique in 46 patients with acute pancreatitis and in the control group of 12 healthy volunteers. At admission (day 1) we found significantly higher pEla-1 level in patients with AP when compared to the control group. During the following days, the concentration of pEla-1 rapidly decreased nearly to undetectable value on the third day. There was no significant difference between patients with mild and severe AP and according to aetiology. We suggest that pEla-1 has a little diagnostic value and does not provide additional information to that of cheaper and more widely available serum amylase and lipase.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.